by Peter Ciszewski | Jan 16, 2018
Alisa Shakarian of Cambridge Biomarketing discusses the challenges pharma and biotech companies face in bringing drugs into the rare disease market.
by Peter Ciszewski | Jan 16, 2018
Sam Falsetti, PhD of Cambridge Biomarketing discusses some of the biotech and rare disease successes of 2017, including the emergence of RNA therapies with the approval of Exondys 51 for Duchenne muscular dystrophy, as well as gene and CAR-T therapies that have had...
by Peter Ciszewski | Jan 15, 2018
The Food and Drug Administration (FDA) expanded the approved use of GlaxoSmithKline’s Nucala (mepolizumab) to treat adult patients with eosinophilic granulomatosis with polyangiitis (EGPA), a rare autoimmune disease that causes vasculitis, an inflammation in the...
by Peter Ciszewski | Jan 4, 2018
Cantex Pharmaceuticals announced that the U.S. Food and Drug Administration (FDA) has granted Orphan Drug Designation to CX-01 for the treatment of acute myeloid leukemia (“AML”). CX-01 is an investigational agent that has the potential to enhance the...
by Peter Ciszewski | Jan 4, 2018
Amit Rakhit, MD, MBA, Chief Medical and Portfolio Officer of Ovid Therapeutics, discusses his company’s approach in developing treatments for patients with rare neurologic disorders. Ovid Therapeutics is a biopharmaceutical company focused exclusively on...
